India Infectious Disease Therapeutics Market Analysis

India Infectious Disease Therapeutics Market Analysis


$ 3999

By 2030, it is anticipated that the Indian infectious disease therapeutics market will reach a value of $3.84 Bn from $2.18 Bn in 2022, growing at a CAGR of 7.4% during 2022-2030. Infectious Disease Therapeutics in India is dominated by a few domestic pharmaceutical companies such as Cadila Healthcare, Lupin Limited, and Sun Pharmaceutical. The Infectious Disease Therapeutics market in India is segmented into different therapeutic areas and different disease types. The major factors affecting the Indian infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the amount of healthcare funding for infectious disease treatment in various areas of India.

ID: IN10INPH038 CATEGORY: Pharmaceuticals GEOGRAPHY: India AUTHOR: Dr. Vishwa Modhia

Buy Now

India Infectious Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the Indian infectious disease therapeutics market will reach a value of $3.84 Bn from $2.18 Bn in 2022, growing at a CAGR of 7.4% during 2022-2030.

India is a lower middle-income, developing country located in Southern Asia bordering the Arabian Sea and the Bay of Bengal. According to the World Factbook, India is extremely vulnerable to infectious diseases. Food or waterborne infections include bacterial diarrhoea, hepatitis A and E, and typhoid fever. Two vector-borne diseases are dengue fever, Crimean-Congo haemorrhagic fever, Japanese encephalitis, and malaria. Leptospirosis and rabies are two other infectious diseases unique to India.

The Indian government has launched a number of programmes and policies to promote access to infectious illness treatment. The National Vector Borne Disease Reduce Programme is one such initiative that tries to control the spread of vector-borne diseases such as malaria, dengue fever, and chikungunya. According to a report by the Indian Brand Equity Foundation, the Indian pharmaceutical market is expected to be worth around US$41 Bn in 2020, with anti-infective medications accounting for a significant portion of that figure. India's government spends 3% of its GDP on healthcare.

India Infectious Disease Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

India is also a major manufacturer of vaccinations, including polio, measles, and rotavirus vaccines. The Serum Institute of India is the world's largest vaccine factory, generating more than 1.5 Bn doses of vaccines each year. In recent years, India has also worked to address the issue of antimicrobial resistance (AMR), which has become a global concern. Infectious disorders such as tuberculosis, malaria, dengue fever, and HIV/AIDS are prevalent in India. In India, infectious illness medicines have been a key focus of research and development. The Indian government has established a number of programmes to promote antibiotic stewardship and to stimulate the discovery of novel antibiotics and alternative treatments. India has a massive workforce and population (almost half of the population is under the age of 25). These aspects could boost India's infectious disease therapeutics market.

Market Restraints

Developing new pharmaceuticals and therapies necessitates adhering to regulatory rules established by organisations such as India's Central Drugs Standard Control Organization (CDSCO). These requirements can be complicated and time-consuming, resulting in delays and higher expenses. Poverty, inequality, and informality are pervasive in India. Infectious disorders such as tuberculosis, malaria, and dengue fever are prevalent in India. This heavy load can make developing effective therapies and conducting clinical trials difficult. These factors may deter new entrants into the Indian infectious disease therapeutics market.

Competitive Landscape

Key Players

  • Serum Institute of India - Serum Institute of India is a leading Indian biotech company that develops and manufactures a range of vaccines, including those for infectious diseases such as polio, measles, and rubella
  • Bharat Biotech - Bharat Biotech is an Indian biotechnology company that develops and manufactures vaccines and immunotherapies for infectious diseases such as hepatitis B, polio, and influenza
  • Cadila Healthcare - Cadila Healthcare is an Indian pharmaceutical company that develops and manufactures a range of therapeutics, including antibiotics and antivirals
  • Lupin Limited - Lupin Limited is an Indian pharmaceutical company that develops and manufactures a range of generic drugs, including those for infectious diseases such as HIV/AIDS and tuberculosis
  • Sun Pharmaceutical Industries - Sun Pharmaceutical Industries is an Indian multinational pharmaceutical company that develops and manufactures a range of therapeutics, including antivirals and antibiotics

Recent Notable Updates

January 2023: Sun Pharmaceutical announced the acquisition of three brands from Aksigen Hospital Care, a Mumbai-based research-driven healthcare business with over two decades of experience in the healthcare field: Disperzyme, Disperzyme-CD, and Phlogam. The Drugs Controller General of India ("DCGI") has approved all of the brands for postoperative inflammation in patients having minor surgery and dental treatments.

December 2022: Cadila Pharmaceuticals has signed an Investment Intention Form (IIF) with the Government of Odisha to establish a pharmaceutical formulation manufacturing unit under the newly launched Industrial Policy 2022 of the Odisha government. With an initial investment of Rs 100 crores, the proposed green field pharmaceutical formulations manufacturing complex in Malipada, Bhubaneswar, is expected to be one of the largest pharma manufacturing units in the region. The Odisha government would expedite clearances to aid in the establishment of the aforementioned project.

Healthcare Policies and Reimbursement Scenarios

The Central Drugs Standard Control Organization (CDSCO), a branch of the Ministry of Health and Family Welfare, regulates infectious disease medicines in India. The CDSCO is in charge of ensuring the safety, effectiveness, and high quality of all medicines and medical equipment, particularly those used to treat infectious diseases. In addition to the CDSCO, other regulatory bodies in India that may be involved in the regulation of infectious disease therapeutics include the Indian Council of Medical Research (ICMR), which provides guidance on the use of new treatments within the healthcare system, and the National Health Systems Resource Centre (NHSRC), which provides technical assistance to the Ministry of Health and Family Welfare.

In India, the funding of infectious disease medicines is managed by a combination of governmental and private health insurance providers, such as the Aayushman Bharat scheme. These therapies are either partially or completely covered by insurance, depending on the patient's insurance coverage and the type of treatment. In India, the reimbursement procedure is tier-based, with different levels of coverage depending on the type of insurance coverage and the type of treatment sought. Treatments for life-threatening infectious diseases like HIV or tuberculosis, for example, are often covered at a higher rate than treatments for less serious infections. Treatment must be approved by the Drugs Controller General of India (DCGI) before it may be reimbursed.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Infectious Disease Therapeutics Segmentation

By Mode of Treatment (Revenue, USD Billion):

  • Vaccines
  • Drugs

By Applications (Revenue, USD Billion):

  • HIV/AIDS
  • Influenza
  • Hepatitis
  • Malaria
  • Tuberculosis
  • Others

By Disease Type (Revenue, USD Billion):

  • Viral Diseases
  • Bacterial Diseases
  • Fungal Diseases
  • Parasitic Diseases
  • Others

By Target Organism (Revenue, USD Billion):

  • Antibiotics
  • Antivirals
  • Antifungals
  • Anti-Parasitic
  • Others

By End User (Revenue, USD Billion):

  • Hospitals and Clinics
  • Ambulatory Care Centers
  • Others

Insights10 will provide you with the reports within 10 key parameters which are:

  1. Market Overview
  2. Market Growth Drivers & Restraints
  3. Epidemiology of Disease Type
  4. Market Segmentation
  5. Market Share
  6. Competitive Landscape
  7. Key Company Profiles
  8. Healthcare Policies & Regulatory Framework
  9. Reimbursement Scenario
  10. Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

 

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

 

 

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and  Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.

 

 

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing the regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue/volume
  • ​Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.

The Central Drugs Standard Control Organization (CDSCO), a branch of the Ministry of Health and Family Welfare, regulates infectious disease medicines in India.

In India, the funding of infectious disease medicines is managed by a combination of governmental and private health insurance providers, such as the Aayushman Bharat scheme.

Infectious Disease Therapeutics in India is dominated by domestic pharmaceutical companies such as Cadila Healthcare, Lupin Limited and Sun Pharmaceutical.


This report addresses

  • Intelligent insights to take informed business decisions
  • Qualitative, acute and result oriented market analysis
  • Market size and forecasts from 2022 to 2030
  • Opportunities for expansion and in-depth market analysis
  • Segmentation and regional revenue forecasts
  • Analysis of the market share and competitive landscape
  • Strategic Recommendations to chart future course of action
  • Comprehensive Market Research Report in PDF and PPT formats

Need more?

  • Ask our analyst how this study was put together to learn more
  • Discuss additional requirements as part of the free customisation
  • Add more countries or regions to the scope 
  • Get answers to specific business questions 
  • Develop the business case to launch the product
  • Find out how this report may influence your business revenue
Last updated on: 12 December 2023
Updated by: Shivam Zalke

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up